Sex Differences in Lecanumab's Effectiveness and Skepticism about its Clinical Benefit

This chapter explores the sex differences in the effectiveness of Lecanumab, a drug for Alzheimer's disease, with delayed disease progression of 43% in men and only 12% in women. It also discusses concerns raised about the drug's effectiveness in women and the skepticism surrounding its clinical benefit.